These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171 [TBL] [Abstract][Full Text] [Related]
24. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Moon DRC; Lee DK; Kim SH; You YS; Kwon OW Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506 [TBL] [Abstract][Full Text] [Related]
25. Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch. Salcedo-Villanueva G; Feria-Anzaldo E; Romo-Aguas JC; Lisker-Cervantes A; González-Dibildox A; Moreno-Paramo E; Medina-Andrade AA; Velez-Montoya R; García-Aguirre G; Morales-Cantón V; Quiroz-Mercado H Int Ophthalmol; 2019 Sep; 39(9):2023-2031. PubMed ID: 30386955 [TBL] [Abstract][Full Text] [Related]
26. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Effects of Intravitreal Aflibercept and Ranibizumab on Systemic Inflammatory and Cardiovascular Biomarkers in Patients with Neovascular Age-related Macular Degeneration. Erdem B; Gok M Curr Eye Res; 2021 Sep; 46(9):1387-1392. PubMed ID: 33471564 [No Abstract] [Full Text] [Related]
28. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334 [TBL] [Abstract][Full Text] [Related]
29. INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial. Hatz K; Prünte C Retina; 2017 Jun; 37(6):1185-1192. PubMed ID: 27652915 [TBL] [Abstract][Full Text] [Related]
30. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept. Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059 [TBL] [Abstract][Full Text] [Related]
31. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Mantel I; Dirani A; Zola M; Parvin P; De Massougnes S; Bergin C Retina; 2019 May; 39(5):906-917. PubMed ID: 29370035 [TBL] [Abstract][Full Text] [Related]
32. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442 [TBL] [Abstract][Full Text] [Related]
33. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Marquis LM; Mantel I Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1591-1596. PubMed ID: 32399582 [TBL] [Abstract][Full Text] [Related]
34. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645 [TBL] [Abstract][Full Text] [Related]
35. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S; Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055 [TBL] [Abstract][Full Text] [Related]
37. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633 [TBL] [Abstract][Full Text] [Related]